Targeting Hims & Hers, F.D.A. Takes on a New Type of Drug Advertisernews2025-09-12T22:09:11+00:00September 12th, 2025|The New York Times|
Ozempic Maker Novo Nordisk to Cut 9,000 Jobsnews2025-09-10T15:46:41+00:00September 10th, 2025|The New York Times|
Where U.S. Medicines Are Made and How Trump’s Tariffs Could Affect Themnews2025-08-24T03:39:58+00:00August 24th, 2025|The New York Times|
Novo Nordisk, Ozempic Drugmaker, Sees Stock Plunge 20% After Profit Warningnews2025-07-29T17:51:03+00:00July 29th, 2025|The New York Times|
Novo Nordisk to Replace C.E.O. After Losing Edge in Weight-Loss Drugsnews2025-05-16T16:17:20+00:00May 16th, 2025|The New York Times|
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drugnews2025-05-12T00:08:25+00:00May 12th, 2025|The New York Times|
What to Know About Eli Lilly’s Daily Pill for Weight Lossnews2025-04-17T21:24:51+00:00April 17th, 2025|The New York Times|
Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycatsnews2025-04-16T14:43:02+00:00April 16th, 2025|The New York Times|
Weight Loss Drug Will Be Offered for $499 a Month for Some Patientsnews2025-03-05T19:09:26+00:00March 5th, 2025|The New York Times|
Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovynews2025-02-05T19:24:38+00:00February 5th, 2025|The New York Times|
